CryoPort Inc (CYRX)

NASD · Industrials · Integrated Freight & Logistics · USA

CryoPort Inc is a small cap company (market value between $300 million and $2 billion) in the Integrated Freight & Logistics industry.

CryoPort provides integrated, temperature-controlled supply chain solutions for life sciences, particularly cell and gene therapy markets. The company delivers logistics, biostorage, cryopreservation services, and cryogenic systems manufacturing to biopharmaceutical companies, research institutions, and government agencies worldwide. Its services support safe handling and delivery of temperature-sensitive biological materials from preclinical development through commercial distribution.

From its FY2025 annual report (Form 10-K)

Intrinsic value, DCF valuation, financial health and value investing analysis for the CryoPort Inc stock.

Our verdict on CYRX

Overvalued: intrinsic value $5.32 per share, market price $19.74, margin of safety -271.3% (as of 2026-11-17).

A 0.8x revenue multiple, discounted for its losses, values the shares at $5.32; the price of $19.74 is 271% above that value.

ETFs with the most weight in CYRX

17 more funds hold it; the full list is part of the paid plan.

More on CYRX

Browse

Peers in Integrated Freight & Logistics

All 32 Integrated Freight & Logistics stocks

Cheaper than CYRX in Integrated Freight & Logistics

8 more in this industry show a wider margin of safety.

Is CYRX undervalued or overvalued?

CYRX is overvalued (as of the 2026-11-17 close). A 0.8x revenue multiple, discounted for its losses, values the shares at $5.32; the price of $19.74 is 271% above that value.

What is the intrinsic value of CYRX?

$5.32 per share (as of the 2026-11-17 close), against a market price of $19.74. That is a margin of safety of -271.3%. The value comes from the one valuation method that applies to this company, recomputed every night after the US close.